Tag Archives: Genentech
Dear Research Advocate:
Yesterday, the Budget Conference Committee, chaired by Sen. Patty Murray (D-WA) and Rep. Paul Ryan (R-WI-01), met for the first time. The committee only has until December 13 to accomplish its task of producing at least a short-term budget. Expectations are modest considering the short timeline, the House and Senate recess schedules, and the number of issues declared “off the table.” There is some talk of replacing sequestration, at least for the remainder of FY14, with selected cuts. In order to assure that research is not cut and in fact is prioritized for an increase, many stakeholders must speak up. It is essential that our issue is discussed as a priority every day in this 43-day countdown — in the media, in hometown districts, by staffers and by our elected officials. Please be sure to speak out. Urge your Members of Congress to advocate on your behalf — and on behalf of all who are depending on research for health — to their colleagues on the Budget Conference Committee.
Sequestration really must go! Useful facts to bolster our case about how sequestration is stalling scientific R&D in this country — to the detriment of business and consumers alike — is now at the ready. Columnist Gerald F. Seib of The Wall Street Journal points to many consumer products and their components that have origins in federally supported basic research, adding billions of dollars to our economy over the decades. And the Science Coalition has released a new report Sparking Economic Growth 2.0 highlighting 100 companies whose beginnings were aided by federally funded university research. Think of Google’s roots in NSF funding and Genentech’s in NIH, for just two prominent examples. The report describes the role these research-based companies play in bringing transformative innovations to market, creating jobs and contributing to economic growth. It’s all too easy to forget, once a business is thriving, how taxpayer funding helped them get its start. Continue reading →